Lazard Asset Management’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Lazard Asset Management’s Portfolio ICPT Stock Details ICPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-41,037	Closed	-$551K	–	2605
2023 Q1	$551K	Hold	41,037	–	–	﹤0.01%	1094
2022 Q4	$507K	Sell	41,037 -16,158	-28%	-$229K	﹤0.01%	1121
2022 Q3	$797K	Buy	57,195 +35,753	+167%	+$576K	﹤0.01%	1021
2022 Q2	$296K	Sell	21,442 -40,173	-65%	-$643K	﹤0.01%	1204
2022 Q1	$1M	Buy	61,615 +19,194	+45%	+$301K	﹤0.01%	996
2021 Q4	$691K	Buy	+42,421	New	+$715K	﹤0.01%	1056
2021 Q1	–	Sell	-7,653	Closed	-$189K	–	2075
2020 Q4	$189K	Buy	7,653 +7,004	+1,079%	+$232K	﹤0.01%	1107
2020 Q3	$26K	Sell	649 -6,146	-90%	-$282K	﹤0.01%	1371
2020 Q2	$325K	Buy	6,795 +5,439	+401%	+$420K	﹤0.01%	866
2020 Q1	$85K	Buy	+1,356	New	+$122K	﹤0.01%	1035

Other funds holding ICPT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

DCM

DG Capital Management New York $326M AUM 39.67% 1-Year Est. Return

Lazard Asset Management's ICPT Position: Q2 2023 in Review

Lazard Asset Management sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q2 2023, closing a stake of 41,037 shares — an estimated $551K sold.

Lazard Asset Management first reported a position in ICPT in Q1 2020 and held it in 10 quarters. The position peaked at $1M in Q1 2022. 126 funds tracked by Wall St. Rank hold ICPT as of Q2 2023.

Lazard Asset Management reported no remaining Intercept Pharmaceuticals, Inc. position as of Q2 2023 after selling out during the quarter.
Lazard Asset Management sold 41,037 Intercept Pharmaceuticals, Inc. shares in Q2 2023, an estimated $551K.
Lazard Asset Management first reported a position in Intercept Pharmaceuticals, Inc. in Q1 2020 and held it in 10 quarters.
Lazard Asset Management's Intercept Pharmaceuticals, Inc. position peaked at $1M in Q1 2022.
126 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q2 2023.

Based on Lazard Asset Management's 13F filing for Q2 2023, filed 15 Aug 2023.